ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, announced it has been named one of the 50 most successful and innovative technology companies of the Pittsburgh region by the Pittsburgh Technology Council.
Shortlisted for the Health IT Innovator of the Year Award, ERT has been recognized for its suite of innovative clinical trial solutions that pharmaceutical researchers rely on to determine the safety and effectiveness of new medical treatments. ERT’s electronic Clinical Outcome Assessment (eCOA), Cardiac Safety, Respiratory, Imaging, Real World Evidence and Trial Oversight solutions improve clinical trial efficiencies, overcome the limitations of traditional paper-and-pencil approaches, and deliver the highest quality patient data so that sponsors can accelerate clinical development and get treatments to the patients who need them sooner.
“We’re honored to receive the Tech 50 recognition and to be considered a leading health technology company not only in Pittsburgh, but around the globe,” said Jim Corrigan, President and CEO, ERT. “It’s a great source of pride for our employees knowing the solutions we deliver play a key role in the clinical research that leads to treatment and cures for diseases affecting millions of patients worldwide.”
Read More: Athena Software Releases New and Enhanced Electronic Health Documentation Feature
For more information on ERT’s suite of eClinical solutions, visit ert.com.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.